Cardiotoxicity
0
Pipeline Programs
6
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Lantheus Medical ImagingMA - Bedford
1 programEarly Detection of Broken Hearts in Cancer PatientsN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
VentriPoint DiagnosticsV-echo
Servierechocardiography, computed tomography
Lantheus Medical ImagingEarly Detection of Broken Hearts in Cancer Patients
Clinical Trials (3)
Total enrollment: 243 patients across 3 trials
Artificial Intelligence for Reconstruction of Echocardiography Studies
Start: Apr 2026Est. completion: Nov 2030120 patients
N/ANot Yet Recruiting
Atherosclerosis in Chemotherapy-related Cardiotoxicity
Start: Nov 2021Est. completion: Mar 202580 patients
N/ACompleted
Early Detection of Broken Hearts in Cancer Patients
Start: Jun 2013Est. completion: Sep 201543 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
6 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.